WallStSmart
BLTE

Belite Bio Inc ADR

NASDAQ: BLTE · HEALTHCARE · BIOTECHNOLOGY

$151.97
-0.77% today

Updated 2026-06-05

Market cap
$5.54B
P/E ratio
P/S ratio
EPS (TTM)
$-2.54
Dividend yield
52W range
$56 – $200
Volume
0.2M

Belite Bio Inc ADR (BLTE) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$17000.00$30000.00$198000.00$399000.00$449000.00
Gross profit$-17000.00$-30000.00$-198000.00$-399000.00$-449000.00
Gross margin
R&D$3.69M$7.42M$8.87M$24.84M$29.94M$45.38M
SG&A$2.06M$2.38M$3.95M$6.82M$10.06M$38.83M
Operating income$-5.74M$-9.80M$-12.82M$-31.67M$-40.00M$-84.21M
Operating margin
EBITDA$-5.73M$-9.64M$-12.43M$-31.20M$-35.67M$-84.21M
EBITDA margin
EBIT$-5.74M$-9.67M$-12.63M$-31.60M$-36.12M
Interest expense$21000.00$5000.00$16000.00$25000.00$20000.00$2000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-5.75M$-9.67M$-12.65M$-31.63M$-36.14M$-77.61M
Net income growth (YoY)-68.0%-30.9%-150.1%-14.3%-114.7%
Profit margin

Frequently asked questions

How much free cash flow does BLTE generate?

BLTE produced $-37.17M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BLTE's balance sheet healthy?

BLTE holds $352.93M in cash and equivalents against — in long-term debt, on $770.49M of shareholder equity. That debt is best read against the cash flow the business throws off each year.